法国为21M欧元的内分泌硬化唾液测试提供了资金,但专家质疑测试的有效性和临床价值。 France funds €21M endometriosis saliva test, but experts question its validity and clinical value.

法国在Endotest投资了2 100万欧元,这是由启动的Ziwig开发的以唾液为基础的子宫内分泌诊断工具,将它作为非侵入性突破加以推广。 France has invested 21 million euros in the Endotest, a saliva-based endometriosis diagnostic tool developed by startup Ziwig, promoting it as a non-invasive breakthrough. 尽管政府支持并声称有大赦国际和微型RNA技术,但由于研究有限、不具代表性和缺乏独立核查,专家们质疑其有效性。 Despite government backing and claims of AI and microRNA technology, experts question its validity due to limited, unrepresentative studies and lack of independent verification. 法国卫生局承认该测试的诊断性能,但强调其临床用途仍未得到证实,并将偿还限于其他成像失效的情况。 The French Health Authority acknowledges the test’s diagnostic performance but stresses its clinical utility remains unproven and restricts reimbursement to cases where other imaging fails. 批评者警告说,对 " 定极 " 的高度关注有可能转移其他研究(例如改进超声波)的资金,并可能阻碍更广泛的创新。 Critics warn the heavy focus on Endotest risks diverting funding from other research, such as improved ultrasound, and may hinder broader innovation.